Brainstorm Cell Therapeutics (BCLI) PT Set at $9.00 by Maxim Group

Maxim Group set a $9.00 target price on Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note issued to investors on Monday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Separately, ValuEngine raised Brainstorm Cell Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 13th.

Shares of Brainstorm Cell Therapeutics opened at $4.06 on Monday, MarketBeat.com reports. The company has a market cap of $79.31 million, a price-to-earnings ratio of -15.62 and a beta of 1.86. Brainstorm Cell Therapeutics has a 12-month low of $3.95 and a 12-month high of $4.01.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its earnings results on Monday, May 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. equities analysts forecast that Brainstorm Cell Therapeutics will post -0.59 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in BCLI. Renaissance Technologies LLC lifted its holdings in shares of Brainstorm Cell Therapeutics by 396.9% during the fourth quarter. Renaissance Technologies LLC now owns 114,550 shares of the biotechnology company’s stock worth $449,000 after buying an additional 91,495 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of Brainstorm Cell Therapeutics by 330.0% during the fourth quarter. Deutsche Bank AG now owns 98,590 shares of the biotechnology company’s stock worth $386,000 after buying an additional 75,664 shares during the last quarter. Finally, Clearline Capital LP acquired a new position in shares of Brainstorm Cell Therapeutics during the fourth quarter worth approximately $208,000. 9.56% of the stock is owned by hedge funds and other institutional investors.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Stox  24-Hour Trading Volume Hits $1.55 Million
Stox 24-Hour Trading Volume Hits $1.55 Million
Dero Hits 24-Hour Volume of $31,012.00
Dero Hits 24-Hour Volume of $31,012.00
Propy  Reaches 24 Hour Trading Volume of $8.56 Million
Propy Reaches 24 Hour Trading Volume of $8.56 Million
$0.62 Earnings Per Share Expected for Cars.com Inc.  This Quarter
$0.62 Earnings Per Share Expected for Cars.com Inc. This Quarter
Brokerages Anticipate Blackbaud, Inc.  Will Post Earnings of $0.66 Per Share
Brokerages Anticipate Blackbaud, Inc. Will Post Earnings of $0.66 Per Share
$0.28 EPS Expected for Clearwater Paper Corp  This Quarter
$0.28 EPS Expected for Clearwater Paper Corp This Quarter


Leave a Reply

© 2006-2018 Ticker Report. Google+.